Skip to main content
JAMA Network logoLink to JAMA Network
. 2022 Apr 22;327(19):1929. doi: 10.1001/jama.2022.7048

Incorrect y-Axis and Panel Labels in Figure

PMCID: PMC9034436  PMID: 35452086

In the Original Investigation titled “Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial,” published in the January 5, 2021, issue of JAMA,1 the labels for some of the y-axes and panels were incorrect. Figure 2 parts A, C, and D should have included disease recurrence or death (instead of just mortality) in the labels for the panels and y-axes. This article has been corrected online.

Reference

  • 1.Wang X, Wang SS, Huang H, et al. ; South China Breast Cancer Group (SCBCG) . Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325(1):50-58. doi: 10.1001/jama.2020.23370 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA are provided here courtesy of American Medical Association

RESOURCES